

**KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE**

**SALES WORLDWIDE**

**\$8.0**  
billion

**+7.5%**<sup>1</sup>  
on organic basis\*

**STRONG PERFORMANCE ACROSS ABBOTT<sup>2</sup>**

SALES ON ORGANIC BASIS\*

**+10.5%**  
MEDICAL DEVICES

**+6.2%**  
DIAGNOSTICS

**+5.1%**  
NUTRITION

**+6.1%**  
ESTABLISHED PHARMACEUTICALS

**RAISED FULL-YEAR 2019 GUIDANCE<sup>3</sup> ON ALREADY STRONG FORECAST**

**\$3.21 to \$3.27**

Adjusted diluted EPS midpoint reflects double-digit growth

**7% to 8%**

Organic sales growth



**FREESTYLE LIBRE**

**SALES UP 73%**  
ON ORGANIC BASIS<sup>4</sup>

- ▶ Simplifying diabetes management just got simpler – the FreeStyle<sup>®</sup> LibreLink<sup>†</sup> and LibreLinkUp<sup>‡</sup> apps are now available for Android users
- ▶ New data show the use of the FreeStyle<sup>®</sup> Libre System significantly reduces glucose<sup>§</sup> levels for people living with Type 2 diabetes on insulin therapy

**MITRACLIP**

**SALES UP 31%**

ON ORGANIC BASIS<sup>5</sup>



- ▶ The new expanded indication for MitraClip<sup>®</sup> to treat secondary mitral regurgitation significantly increases the number of people that can be helped with MitraClip
- ▶ MitraClip<sup>®</sup> G4 – Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature

**CORE LABORATORY DIAGNOSTICS**

**SALES UP 9%**

ON ORGANIC BASIS<sup>6</sup>



- ▶ Continued strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency
- ▶ Alinity<sup>™</sup>s – Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe

\* Organic sales growth excludes the prior year first- and second-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 17, 2019, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).

<sup>†</sup> The FreeStyle LibreLink app is compatible with NFC-enabled smartphones running Android OS 5.0 or higher and iPhone 7 or later running iOS 11 or later. Use of the FreeStyle LibreLink app requires registration with LibreView, a service provided by Abbott and Newyu, Inc. LibreLinkUp is a mobile application developed and provided by Newyu, Inc.

<sup>‡</sup> LibreLinkUp is compatible with Android phones running OS 4.4 and later and iPhones running iOS 10 and later.

<sup>§</sup> Kröger, J., Fasching, P., Hanaire, H. Meta-Analysis of Three, Real-World, Chart Review Studies to Determine the Effectiveness of FreeStyle Libre Flash Glucose Monitoring System on HbA1c in Adults with Type 2 Diabetes. Presented at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California, USA.

<sup>1</sup> On a GAAP basis, Abbott sales increased 2.7%. <sup>2</sup> On a GAAP basis, Medical Devices sales increased 6.4%; Diagnostics sales increased 1.7%; Nutrition sales increased 0.9%; and Established Pharmaceuticals sales decreased 1.8%. <sup>3</sup> Adjusted diluted EPS excludes specified items. Full-year 2019 GAAP EPS guidance of \$2.06 to \$2.12. Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. <sup>4</sup> On a GAAP basis, FreeStyle Libre sales increased 63.9%. <sup>5</sup> On a GAAP basis, MitraClip sales increased 26.7%. <sup>6</sup> On a GAAP basis, Core Laboratory Diagnostics sales increased 3.6%.

**FORWARD-LOOKING STATEMENTS**

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.